Abbvie INC 8-K filings

AbbVie Inc. has successfully issued $9.93 billion in senior notes to fund its acquisition of Apogee Therapeutics and for general corporate purposes.

AbbVie Inc. announced robust second-quarter 2026 financial results, with net revenues up 10.2% and adjusted diluted EPS increasing 22.9%, alongside a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion.

AbbVie Inc. announced updated 2026 financial guidance, incorporating $291 million in acquired IPR&D and milestones expense for the second quarter, impacting diluted EPS by $0.17.

AbbVie Inc. reported the results of its 2026 Annual Meeting of Stockholders, detailing votes on director elections, auditor ratification, executive compensation, and charter amendments.

AbbVie Inc. announced first-quarter 2026 financial results, exceeding expectations with a 12.4% increase in net revenues and raising its full-year adjusted diluted EPS guidance.

AbbVie Inc. reported preliminary Q1 2026 results, noting $744 million in acquired IPR&D and milestones expense, impacting EPS by $0.41 and adjusting full-year guidance.

AbbVie Inc. successfully completed an underwritten public offering of $8 billion in senior notes across multiple tranches with varying maturities and interest rates.

AbbVie Inc. announced an underwriting agreement to issue $8 billion in senior notes across multiple tranches to repay existing debt and for general corporate purposes.

AbbVie announced record net sales for 2025, driven by its diversified growth platform, and provided an optimistic adjusted diluted EPS guidance for 2026.

AbbVie Inc. updated its full-year and fourth-quarter 2025 adjusted diluted EPS guidance, reflecting a $1.3 billion acquired IPR&D and milestones expense.

AbbVie reported strong third-quarter net revenues of $15.776 billion, an increase of 9.1%, and raised its full-year 2025 adjusted diluted EPS guidance.

AbbVie Inc. has revised its full-year and third-quarter 2025 adjusted diluted earnings per share guidance downward due to a significant $2.7 billion acquired IPR&D and milestones expense.

AbbVie announced a settlement with generic manufacturers, delaying generic versions of its drug RINVOQ in the U.S. until at least April 2037.

AbbVie announced strong second-quarter 2025 financial results, with adjusted diluted EPS increasing 12.1% and net revenues up 6.6%, leading to an upward revision of its full-year adjusted diluted EPS guidance.

AbbVie Inc. has revised its full-year and second-quarter 2025 adjusted diluted earnings per share guidance downwards due to an $823 million acquired in-process research and development and milestones expense incurred in the second quarter.

AbbVie Inc. announces the appointment of Thomas J. Falk to its Board of Directors, adjustments to board size following retirements, and changes to executive compensation, particularly for the incoming Chairman.

AbbVie's first-quarter 2025 results exceeded expectations, driven by strong performance in its immunology and neuroscience portfolios, leading to an increase in the company's full-year adjusted diluted EPS guidance.

AbbVie adjusts its 2025 earnings guidance to incorporate a $248 million expense related to acquired IPR&D and milestones in the first quarter.

AbbVie successfully completes a $4 billion senior notes offering across four tranches with maturities ranging from 2028 to 2055.

AbbVie Inc. has announced the offering of $4 billion in aggregate principal amount of senior notes due in 2028, 2030, 2035 and 2055 to refinance existing debt and for general corporate purposes.

AbbVie announces Robert A. Michael's appointment as Chairman of the Board, succeeding Richard A. Gonzalez, effective July 1, 2025, along with Glenn F. Tilton's retirement from the board.

AbbVie Inc. has established a new $3 billion revolving credit facility maturing in 2030, supplementing its existing $5 billion facility and providing access to $8 billion in total revolving credit.

AbbVie's full-year 2024 results show revenue growth but a decrease in earnings per share, while the fourth quarter saw a loss per share due to an impairment charge, with the company providing 2025 adjusted EPS guidance.

AbbVie will record a $3.5 billion non-cash impairment charge related to the emraclidine intangible asset after Phase 2 trials failed to meet their primary endpoint.

AbbVie has revised its 2024 earnings guidance to incorporate a $1.6 billion charge related to acquired IPR&D and milestones expenses, impacting both Q4 and full-year adjusted diluted EPS.

AbbVie's Senior Vice President, Controller, Kevin K. Buckbee, will retire on March 1, 2025, and will be succeeded by David R. Purdue.

AbbVie announced its third-quarter 2024 financial results, showcasing revenue growth and increased adjusted earnings per share, while also raising its full-year guidance and dividend.

AbbVie has revised its 2024 earnings guidance to include an $82 million expense related to acquired IPR&D and milestones in the third quarter, impacting both GAAP and adjusted non-GAAP diluted earnings per share by $0.04.

AbbVie Inc.'s Board of Directors approved amendments to the company's bylaws, updating the registered agent's address and removing a section challenged in a stockholder class action.

AbbVie's second-quarter results exceeded expectations, driven by strong performance in its ex-Humira portfolio, leading to an increase in the company's full-year adjusted diluted EPS guidance.